Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study)

Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study)

Purpose. An expanded access program (PRIDE study) in Italy to provide ranibizumab 0.5 mg to diabetic macular edema (DME) patients, prior to reimbursement. Methods. Open-label, prospective, phase IIIb study. Majority of patients were not treatment-naïve before enrollment. Patients received ranibizuma...

Full description

Bibliographic Details
Main Authors: Ugo Menchini, Francesco Bandello, Vincenzo De Angelis, Federico Ricci, Luigi Bonavia, Francesco Viola, Elisa Muscianisi, Massimo Nicolò
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2015/324841

Internet

http://dx.doi.org/10.1155/2015/324841

Similar Items